Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

tion against Parkinson's. We look forward to the opportunity to conduct Phase 3 testing, with the goal to bring NLX-P101 to the market for patients in urgent need of a new treatment option."

Drs. During and Kaplitt have been at the forefront of gene therapy research since 1989 and the Phase 2 trial was the culmination of nearly 20 years of progress with their work in gene transfer technology using an adeno-associated virus (AAV) vector (a disabled, non-pathogenic virus). They were the first to demonstrate that AAV could be an effective gene therapy agent in the brain, which they reported in their landmark Nature Genetics paper in 1994. Drs. During, Kaplitt and colleagues subsequently published additional research demonstrating the beneficial effects of AAV-GAD gene therapy for PD in the journal Science in 2002.

About the Phase 2 Study

The trial involved 45 subjects with moderate to advanced PD who were not adequately controlled with current therapies. Medical centers that participated in the study included: Henry Ford Health System; Massachusetts General Hospital; Stanford University School of Medicine; The Feinstein Institute for Medical Research of the North Shore-LIJ Health System; The Ohio State University College of Medicine; University of Colorado School of Medicine; University of Rochester School of Medicine; and Wake Forest University School of Medicine.

Study subjects were randomized to receive either NLX-P101 treatment or sham surgery. Subjects in the NLX-P101 treatment arm received infusions of the genetic material directly into bilateral subthalamic nuclei (STN), a key brain region involved in motor function. Sham-assigned subjects underwent simulation of a bilateral neurosurgical procedure. At the end of each procedure, infusion catheters were removed at the bedside and nothing was left in the brain. All procedures were performed under local anesthesia. All but one of the trial participants were discharg
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 Eli Lilly and Company (NYSE: ... 7 to update the investment community and media on ... conjunction with the 75th American Diabetes Association® Scientific Sessions, ... business, including a review of the Phase III data ... the ADA meeting. The meeting will be ...
(Date:3/30/2015)... ISELIN, N.J. , March 30, 2015 /PRNewswire/ ... a medical device company focused on non-invasive continuous ... it has achieved its wireless mobile communication milestone, ... sensor to transmit data to any mobile platform. ... the strategic transformation of the Company,s technology from ...
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
Breaking Medicine Technology:Lilly Announces Date for Diabetes Investor Meeting 2Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone 2Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5
... Colo., March 29, 2011 Encision Inc. (Pink Sheets: ... laparoscopic safety have become intensive topics of discussion in ... Surgery Magazine (March 2011).  The potential complications from laparoscopic ... probably prompted by a recent California case.  The issue ...
... 29, 2011 BioDrain Medical, Inc. (OTC Bulletin ... FDA cleared Streamway™ System for automated surgical fluid ... installation of its patented Streamway™ System in a ... several procedures utilizing the Streamway System and the ...
Cached Medicine Technology:Stray Energy Burns Become a "Hot Topic" in Recent Publications 2Stray Energy Burns Become a "Hot Topic" in Recent Publications 3BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital 2BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital 3
(Date:3/30/2015)... GenSight ®, provider of an Enterprise Portfolio Management ... Forrester Wave™: Strategic Planning For The [Business Technology] BT ... GenSight as a leader and gave the company the ... analytics, corporate strategy, assessment, direction and life cycle support ... Leaders category. , According to the report: GenSight ...
(Date:3/30/2015)... 2015 Follow us on ... are used as tracers to diagnose and treat ... is driven by the increase in the number ... cardiology, neurology, pulmonology, and oncology. Diagnostic radiopharmaceuticals represent ... of radioisotopes in diagnostic imaging. While cardiovascular and ...
(Date:3/30/2015)... El Segundo, CA (PRWEB) March 30, 2015 ... drug tests to accommodate the needs of every industry that ... As employers face compliance mandates or seek new ways to ... is adding new drug panels that will help detect substance ... “Certain industries have mandated drug tests,” said Corra Group Co-Founder, ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Cutting-edge doctors ... Health 2015 Conference because of the opportunities to present ... year’s conference will highlight parents of recovered children, who ... Mary Romaniec, will debut her book Victory over Autism: ... Family. Free copies of Victory over Autism will be ...
(Date:3/30/2015)... Bunion Bootie is a great option ... members, friends...and yourself and save. For a limited time only ... 10%, on top of discounts already offered when buying more ... The more Bunion Booties purchased, the more money is saved. ... Bunion Bootie can be worn comfortably and easily in almost ...
Breaking Medicine News(10 mins):Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:Corra Group Adds New Employment Screening Drug Test Solutions for Clients in Every Industry 2Health News:Corra Group Adds New Employment Screening Drug Test Solutions for Clients in Every Industry 3Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 3Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2
... release is available in French . , ... support to recruit some of its best minds in ... family foundation has generously pledged $2.5 million to support ... University and the Universit du Qubec,s Institut national de ...
... for suspected pulmonary emboli (PE) is rapidly increasing amongst ... positive studies. This may be due to a failure ... with suspected PE, according to a study performed at ... Rhode Island Hospital, Providence, RI. , Current accepted ...
... Teva Announces First Event in Year of Affordable Healthcare ... consumer health group, recently reported that healthcare premiums in ... between 2000 and 2007. With healthcare costs ... claims being filed, many Americans are finding themselves driven ...
... Records Association (EHR Association) seeks broad stakeholder consensus by ... Act of 2009 (ARRA) as well as specific recommendations ... which will be used to determine eligibility for the ... and hospitals. "I,ve been pleased to have the ...
... M.D., has issued the,following press release: , ... a recent flurry of panic about,the H1N1 (swine influenza). ... cancelled. Some even suggested closing the border with Mexico,where ... back,and forth every day. The panic certainly was ...
... result in quick relief for communities that have been ... Feeding America and The Clorox Company ... communities hit by recent flooding in Eastern Kentucky and ... individuals and families are beginning the arduous task of ...
Cached Medicine News:Health News:Cole Foundation injects $2.5 million to bolster leukemia research 2Health News:ER physicians don't follow clinical guidelines for diagnosing possible pulmonary emboli 2Health News:As Healthcare Costs Skyrocket, Local Leaders Gather to Seek a Solution 2Health News:HIMSS Electronic Health Record Association Reaches Out to Key Stakeholders on 'Meaningful Use' of Certified EHRs 2Health News:HIMSS Electronic Health Record Association Reaches Out to Key Stakeholders on 'Meaningful Use' of Certified EHRs 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Feeding America Partner Support Expedites Disaster Relief and Recovery Efforts 2
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: